Wei-Qun Ding

Title: Innovations of Wei-Qun Ding in Chimeric Proteins

Introduction

Wei-Qun Ding is an accomplished inventor based in Edmond, OK (US). He has made significant contributions to the field of biotechnology, particularly in the development of chimeric proteins. With a total of 2 patents, his work focuses on innovative solutions for medical challenges.

Latest Patents

Wei-Qun Ding's latest patents include the development of chimeric proteins with phosphatidylserine binding domains. These proteins comprise soluble Tissue Factor (sTF) and another subunit, such as annexin V. They are designed to promote blood clotting and inhibit cancer by targeting sTF to specific receptors like phosphatidylserine (PS) on activated cells. The applications of these chimeric proteins are vast, as they can treat patients suffering from excessive bleeding due to various conditions, including inborn problems, drug therapy, trauma, or surgery. Additionally, they serve as an anti-cancer therapy by causing blood vessels that feed tumors to become clotted, thereby restricting blood flow to the tumor and leading to its inhibition and potential death.

Career Highlights

Wei-Qun Ding is affiliated with the University of Oklahoma, where he continues to advance his research in the field of biotechnology. His innovative work has garnered attention and respect within the scientific community.

Collaborations

Some of his notable coworkers include Stuart E Lind and Roger G Harrison, Jr. Their collaboration has contributed to the advancement of research in chimeric proteins and their applications.

Conclusion

Wei-Qun Ding's contributions to the field of biotechnology through his innovative patents on chimeric proteins highlight his commitment to addressing critical medical challenges. His work not only promotes advancements in blood clotting therapies but also offers potential solutions for cancer treatment.